Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
Ascitic fluid
Cisplatin-resistance
OvCa
TME
Journal
Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
13
05
2020
revised:
20
12
2020
accepted:
30
12
2020
pubmed:
22
1
2021
medline:
5
3
2022
entrez:
21
1
2021
Statut:
ppublish
Résumé
Platinum resistance in epithelial ovarian cancer (OvCa) is rising at an alarming rate, with recurrence of chemo-resistant high grade serous OvCa (HGSC) in roughly 75 % of all patients. Additionally, HGSC has an abysmal five-year survival rate, standing at 39 % and 17 % for FIGO stages III and IV, respectively. Herein we review the crucial cellular interactions between HGSC cells and the cellular and non-cellular components of the unique peritoneal tumor microenvironment (TME). We highlight the role of the extracellular matrix (ECM), ascitic fluid as well as the mesothelial cells, tumor associated macrophages, neutrophils, adipocytes and fibroblasts in platinum-resistance. Moreover, we underscore the importance of other immune-cell players in conferring resistance, including natural killer cells, myeloid-derived suppressive cells (MDSCs) and T-regulatory cells. We show the clinical relevance of the key platinum-resistant markers and their correlation with the major pathways perturbed in OvCa. In parallel, we discuss the effect of immunotherapies in re-sensitizing platinum-resistant patients to platinum-based drugs. Through detailed analysis of platinum-resistance in HGSC, we hope to advance the development of more effective therapy options for this aggressive disease.
Identifiants
pubmed: 33476723
pii: S1044-579X(21)00003-1
doi: 10.1016/j.semcancer.2020.12.024
pmc: PMC8286277
mid: NIHMS1665718
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Platinum Compounds
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-98Subventions
Organisme : NCI NIH HHS
ID : R01 CA193437
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM127261
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001420
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Oncol Rep. 2014 Nov;32(5):2150-8
pubmed: 25174950
Oncotarget. 2015 May 10;6(13):11310-26
pubmed: 25888637
Front Immunol. 2019 Jun 04;10:1273
pubmed: 31214202
J Clin Invest. 2008 Apr;118(4):1367-79
pubmed: 18340378
Gynecol Oncol. 2017 Oct;147(1):181-187
pubmed: 28698008
Int J Mol Sci. 2018 May 16;19(5):
pubmed: 29772714
Diagnostics (Basel). 2020 Mar 07;10(3):
pubmed: 32156035
Int J Cancer. 2008 Jan 1;122(1):91-9
pubmed: 17893878
Nat Rev Cancer. 2003 Jul;3(7):502-16
pubmed: 12835670
Nat Med. 2017 Mar;23(3):368-375
pubmed: 28165478
Cancer Res. 2015 Aug 1;75(15):3098-107
pubmed: 26081809
J Transl Med. 2015 May 07;13:146
pubmed: 25947066
J Immunother Cancer. 2019 Jul 19;7(1):190
pubmed: 31324218
J Biol Chem. 2016 Jul 1;291(27):13905-13916
pubmed: 27143361
Int J Mol Sci. 2020 Apr 28;21(9):
pubmed: 32354198
Science. 2002 Oct 25;298(5594):850-4
pubmed: 12242449
Oncotarget. 2017 Aug 4;8(38):64607-64621
pubmed: 28969098
Int J Cancer. 2006 Apr 15;118(8):1963-71
pubmed: 16287073
Microcirculation. 2016 Feb;23(2):95-121
pubmed: 26614117
OMICS. 2009 Aug;13(4):345-54
pubmed: 19422301
Semin Cancer Biol. 2021 Dec;77:110-126
pubmed: 32827632
Sci Rep. 2017 Aug 2;7(1):7104
pubmed: 28769043
Onco Targets Ther. 2019 Oct 21;12:8687-8699
pubmed: 31695427
Front Endocrinol (Lausanne). 2017 Apr 07;8:66
pubmed: 28439256
Cancers (Basel). 2018 Aug 10;10(8):
pubmed: 30103384
Int J Clin Exp Pathol. 2015 Aug 01;8(8):9428-33
pubmed: 26464699
J Clin Invest. 2014 Oct;124(10):4614-28
pubmed: 25202979
Cancer Biomark. 2016 Jun 7;17(1):33-40
pubmed: 27314290
Oncogene. 2019 May;38(22):4366-4383
pubmed: 30765860
Br J Cancer. 2017 Nov 21;117(11):1583-1591
pubmed: 29065107
J Nucleic Acids. 2010 Aug 08;2010:
pubmed: 20811617
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
J Gynecol Oncol. 2019 Sep;30(5):e105
pubmed: 31328467
Anticancer Res. 2015 Oct;35(10):5263-70
pubmed: 26408685
Mediators Inflamm. 2015;2015:701067
pubmed: 26648665
J Cell Biochem. 2013 Jan;114(1):21-34
pubmed: 22887554
Cancer Sci. 2014 Aug;105(8):966-73
pubmed: 24826982
Immunol Rev. 2016 Sep;273(1):329-43
pubmed: 27558344
Biochim Biophys Acta. 2013 Oct;1831(10):1533-41
pubmed: 23500888
J Clin Invest. 2016 Oct 3;126(10):3672-3679
pubmed: 27482883
Proc Natl Acad Sci U S A. 2013 May 28;110(22):E1974-83
pubmed: 23645635
Clin Cancer Res. 2005 Sep 1;11(17):6300-10
pubmed: 16144934
Oncol Rep. 2018 May;39(5):2081-2090
pubmed: 29565447
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
Cancer Lett. 2020 Mar 1;472:59-69
pubmed: 31866467
Onco Targets Ther. 2019 Sep 30;12:8015-8022
pubmed: 31686857
Cancer Res. 2006 Aug 15;66(16):7968-75
pubmed: 16912171
Cancer Lett. 1995 May 8;91(2):229-34
pubmed: 7539337
Gynecol Oncol Rep. 2019 Jun 18;29:48-54
pubmed: 31312712
Endocr Rev. 2012 Feb;33(1):109-44
pubmed: 22240241
Cancer Immunol Immunother. 2013 Nov;62(11):1745-56
pubmed: 24092389
Oncotarget. 2016 Nov 15;7(46):75339-75352
pubmed: 27659538
Am J Pathol. 2013 Aug;183(2):576-91
pubmed: 23885715
Gynecol Oncol. 2004 Apr;93(1):170-81
pubmed: 15047232
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cancer Res. 1993 Aug 15;53(16):3830-8
pubmed: 8339295
PLoS One. 2011;6(11):e27690
pubmed: 22110722
Int J Cancer. 2020 Oct 1;147(7):1768-1777
pubmed: 32208517
Chin J Cancer. 2015 Jan;34(1):17-27
pubmed: 25556615
EBioMedicine. 2019 May;43:238-252
pubmed: 31047858
Anticancer Res. 2009 Aug;29(8):2875-84
pubmed: 19661290
Oncogene. 2009 Aug 20;28(33):2940-7
pubmed: 19581928
Sci Rep. 2017 Aug 11;7(1):7958
pubmed: 28801607
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Anticancer Drugs. 2020 Feb;31(2):101-109
pubmed: 31743133
Oncotarget. 2017 Jan 10;8(2):3649-3665
pubmed: 27690299
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
Mod Pathol. 2009 Mar;22(3):373-84
pubmed: 18997734
Oncogene. 2018 Sep;37(37):5127-5135
pubmed: 29789717
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Trends Cancer. 2018 May;4(5):374-384
pubmed: 29709261
Int Immunol. 2015 Dec;27(12):621-32
pubmed: 26138671
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Oncotarget. 2016 Dec 27;7(52):86608-86620
pubmed: 27888810
Am J Transl Res. 2015 Oct 15;7(10):1699-711
pubmed: 26692918
Cancers (Basel). 2018 Oct 29;10(11):
pubmed: 30380628
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Cancers (Basel). 2019 Apr 01;11(4):
pubmed: 30939820
Cancer Res. 2011 Dec 15;71(24):7463-70
pubmed: 22025564
Br J Cancer. 2009 Aug 4;101(3):432-40
pubmed: 19603017
Oncogene. 2017 Jun 22;36(25):3576-3587
pubmed: 28166193
J Cancer. 2017 Aug 25;8(15):2915-2923
pubmed: 28928882
Facts Views Vis Obgyn. 2018 Mar;10(1):5-18
pubmed: 30510663
Cancer Res. 2006 Mar 15;66(6):3006-14
pubmed: 16540649
BMC Med. 2015 Mar 05;13:45
pubmed: 25857315
Neoplasia. 2012 Apr;14(4):259-70
pubmed: 22577342
Curr Cancer Drug Targets. 2011 May;11(4):405-11
pubmed: 21395551
Oncotarget. 2017 Nov 25;8(65):109417-109435
pubmed: 29312618
Cancer Metastasis Rev. 2014 Mar;33(1):17-39
pubmed: 24357056
Cancer Res. 2013 Aug 15;73(16):5016-28
pubmed: 23824740
Front Pharmacol. 2020 Mar 20;11:343
pubmed: 32265714
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Mol Cancer Ther. 2006 Nov;5(11):2613-23
pubmed: 17088436
Gynecol Oncol. 2016 Aug;142(2):225-30
pubmed: 27208536
Cell. 2016 Jul 28;166(3):755-765
pubmed: 27372738
Med Oncol. 2015 Jan;32(1):391
pubmed: 25433947
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Neoplasia. 2008 Oct;10(10):1092-104
pubmed: 18813349
Clin Cancer Res. 2002 Mar;8(3):878-84
pubmed: 11895922
Mol Cancer Res. 2007 Oct;5(10):1015-30
pubmed: 17951402
Mol Cancer. 2019 Mar 30;18(1):70
pubmed: 30927908
Clin Cancer Res. 2009 Jun 1;15(11):3770-80
pubmed: 19470734
Mol Med Rep. 2017 Dec;16(6):9587-9592
pubmed: 29039536
Cancer Res. 2003 Jun 15;63(12):3403-12
pubmed: 12810677
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818791500
pubmed: 30145940
Clin Cancer Res. 2014 Jun 15;20(12):3280-8
pubmed: 24756370
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Dis Model Mech. 2011 Mar;4(2):165-78
pubmed: 21324931
Curr Top Microbiol Immunol. 2011;344:129-48
pubmed: 20680802
Oncotarget. 2016 Aug 2;7(31):49710-49721
pubmed: 27391345
Front Immunol. 2018 Apr 05;9:527
pubmed: 29675018
J Transl Med. 2004 Jun 25;2(1):23
pubmed: 15219235
Int J Cancer. 2020 Apr 15;146(8):2268-2280
pubmed: 31904865
Biomolecules. 2019 Nov 26;9(12):
pubmed: 31779287
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Hum Gene Ther. 2017 Oct;28(10):886-896
pubmed: 28836469
Oxid Med Cell Longev. 2017;2017:2873030
pubmed: 28848618
Int J Gynecol Cancer. 2015 Jan;25(1):42-8
pubmed: 25356535
Oncoimmunology. 2015 Jan 22;4(4):e1001224
pubmed: 26137398
Cancer. 1994 Jul 1;74(1):93-9
pubmed: 8004589
Am J Cancer Res. 2012;2(5):566-80
pubmed: 22957308
Sci Rep. 2015 Dec 15;5:18217
pubmed: 26666576
Gynecol Oncol. 2007 Jul;106(1):75-81
pubmed: 17433425
Gynecol Oncol. 2011 Aug;122(2):361-5
pubmed: 21570711
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
BMC Cancer. 2013 Oct 14;13:476
pubmed: 24124770
Int Immunopharmacol. 2016 Nov;40:184-195
pubmed: 27608303
J Immunol Res. 2019 Feb 25;2019:2368249
pubmed: 30931335
Biochem Soc Trans. 2017 Feb 8;45(1):229-236
pubmed: 28202677
Biomed Res Int. 2017;2017:7943467
pubmed: 28815182
Trends Immunol. 2017 Jul;38(7):526-536
pubmed: 28579319
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56
pubmed: 26224579
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Cell Signal. 2020 Apr;68:109539
pubmed: 31935430
J Ovarian Res. 2012 Nov 15;5(1):34
pubmed: 23153223
Cancer Immunol Immunother. 2012 Aug;61(8):1155-67
pubmed: 22692756
Blood. 2013 May 2;121(18):3599-608
pubmed: 23487023
Mol Pharmacol. 2002 Sep;62(3):660-71
pubmed: 12181443
Cancer Res. 2011 Aug 15;71(16):5522-5534
pubmed: 21742774
Sci Rep. 2018 Aug 21;8(1):12522
pubmed: 30131543
Cancers (Basel). 2020 Jan 24;12(2):
pubmed: 31991604
Cancer Immunol Res. 2015 Sep;3(9):1030-41
pubmed: 26056145
Int J Gynecol Cancer. 2016 May;26(4):671-9
pubmed: 26905331
Cancer Cell. 2003 Apr;3(4):377-86
pubmed: 12726863
Mol Pharmacol. 2004 Jul;66(1):25-32
pubmed: 15213293
Clin Cancer Res. 2002 Apr;8(4):1108-14
pubmed: 11948121
Clin Cancer Res. 2004 Apr 15;10(8):2804-11
pubmed: 15102688
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
Cell Oncol (Dordr). 2016 Oct;39(5):473-481
pubmed: 27444787
Cancer Discov. 2011 Jul;1(2):144-57
pubmed: 22303516
Mol Cell Oncol. 2015 Jan 30;2(3):e995025
pubmed: 27308478
Gynecol Oncol. 2014 Jun;133(3):624-31
pubmed: 24607285
Pharmacol Res. 2016 Apr;106:27-36
pubmed: 26804248
Front Oncol. 2019 Jul 31;9:688
pubmed: 31417869
Biomed Rep. 2017 Sep;7(3):209-213
pubmed: 28811894
Nat Cell Biol. 2019 Apr;21(4):511-521
pubmed: 30886344
Gynecol Oncol. 2018 Apr;149(1):205-213
pubmed: 29395307
Biochem Biophys Res Commun. 2020 Jun 4;526(3):820-826
pubmed: 32273089
Int J Mol Sci. 2019 May 21;20(10):
pubmed: 31117237
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Int J Oncol. 2013 May;42(5):1630-5
pubmed: 23467686
Cancer Immunol Res. 2015 Nov;3(11):1257-68
pubmed: 26138335
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Front Immunol. 2019 Aug 09;10:1782
pubmed: 31456796
J Immunol Res. 2018 Mar 29;2018:2438598
pubmed: 29713652
Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):371-378
pubmed: 30423357
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Cancers (Basel). 2018 Sep 01;10(9):
pubmed: 30200478
Semin Cancer Biol. 2021 Dec;77:29-41
pubmed: 33161141
Cancer Res. 2016 Oct 15;76(20):6017-6029
pubmed: 27569212
Cancer Immunol Immunother. 2010 Feb;59(2):279-91
pubmed: 19727719
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
Science. 2009 Nov 27;326(5957):1216-9
pubmed: 19965464
J Gynecol Oncol. 2013 Jan;24(1):83-91
pubmed: 23346317
Int J Biochem Cell Biol. 2010 Jan;42(1):25-30
pubmed: 19854294
Clin Cancer Res. 2011 Apr 15;17(8):2350-60
pubmed: 21220476
Oncotarget. 2017 Jun 28;8(44):76116-76128
pubmed: 29100297
Blood. 2011 Nov 17;118(20):5498-505
pubmed: 21972293
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Front Oncol. 2013 May 16;3:120
pubmed: 23720710
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5853-9
pubmed: 14676106
Cell Physiol Biochem. 2017;41(2):795-805
pubmed: 28214851
Oncotarget. 2016 Dec 13;7(50):83148-83159
pubmed: 27825119
Cancer Cell. 2011 Sep 13;20(3):300-14
pubmed: 21907922
Gynecol Oncol. 2005 Dec;99(3):704-13
pubmed: 16126266
PLoS One. 2010 Jun 18;5(6):e11198
pubmed: 20585448
Oncogene. 2017 Feb 16;36(7):912-921
pubmed: 27568980
Cancer Med. 2018 Oct;7(10):5047-5056
pubmed: 30133163
Matrix Biol Plus. 2020 Jan 20;6-7:100021
pubmed: 33543019
Cell. 2016 May 19;165(5):1092-1105
pubmed: 27133165
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091744
Extreme Mech Lett. 2018 May;21:25-34
pubmed: 30135864
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30
pubmed: 21746895
J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3
pubmed: 27372564
J Ovarian Res. 2018 Mar 2;11(1):20
pubmed: 29499737
Elife. 2019 Sep 03;8:
pubmed: 31478830
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
Cell Signal. 2016 Aug;28(8):838-49
pubmed: 27075926
Int J Mol Med. 2003 Mar;11(3):337-41
pubmed: 12579336
Br J Cancer. 2019 Feb;120(4):424-434
pubmed: 30718808
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Int J Cancer. 2009 Nov 15;125(10):2450-5
pubmed: 19670329
Semin Cancer Biol. 2021 Dec;77:167-181
pubmed: 32871277
Biochem Biophys Res Commun. 2002 Apr 12;292(4):860-8
pubmed: 11944893
Oral Oncol. 2003 Feb;39(2):157-62
pubmed: 12509969
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
BMC Cancer. 2014 Nov 18;14:837
pubmed: 25408231
Cancers (Basel). 2018 Sep 29;10(10):
pubmed: 30274280
Oncotarget. 2016 Aug 2;7(31):49310-49321
pubmed: 27384479
FASEB J. 2018 Oct;32(10):5365-5377
pubmed: 29763380
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
J Cancer. 2016 Mar 10;7(5):546-54
pubmed: 27053953
Carcinogenesis. 2012 Jan;33(1):20-9
pubmed: 22021907
Am J Pathol. 1995 May;146(5):1029-39
pubmed: 7538264
Sci Rep. 2019 Sep 16;9(1):13316
pubmed: 31527632
Front Oncol. 2015 Nov 02;5:245
pubmed: 26579497
Cancer Res. 2013 Apr 15;73(8):2480-92
pubmed: 23436796
Immunotherapy. 2011 Apr;3(4):539-56
pubmed: 21463194
Oncotarget. 2017 Aug 10;8(44):76843-76856
pubmed: 29100353
Oncol Lett. 2015 Oct;10(4):2584-2590
pubmed: 26622894
Obes Rev. 2016 Nov;17(11):1015-1029
pubmed: 27432523
BMC Med Genomics. 2009 Jun 08;2:34
pubmed: 19505326
Anticancer Res. 2013 Apr;33(4):1409-14
pubmed: 23564780
Commun Biol. 2019 Jul 31;2:281
pubmed: 31372520
Cells. 2019 Sep 13;8(9):
pubmed: 31540259
Cancer Lett. 2011 Apr 1;303(1):47-55
pubmed: 21310528
Trends Cell Biol. 2015 Apr;25(4):234-40
pubmed: 25572304
Am J Pathol. 2007 Mar;170(3):1054-63
pubmed: 17322388
Nature. 2015 Nov 19;527(7578):398
pubmed: 26503049
Int J Mol Sci. 2014 Oct 29;15(11):19700-28
pubmed: 25356505
J Mol Med (Berl). 2013 Mar;91(3):357-68
pubmed: 23052480
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Hum Pathol. 1995 Jan;26(1):86-91
pubmed: 7821921
Cancer Res. 2007 Jun 15;67(12):5708-16
pubmed: 17575137
Oncoimmunology. 2016 Sep 13;5(11):e1232221
pubmed: 27999744
Gynecol Oncol. 2008 Feb;108(2):421-7
pubmed: 18036640
Front Immunol. 2019 Apr 26;10:867
pubmed: 31105696
Cell Death Differ. 2015 Apr;22(4):549-59
pubmed: 25656654